Filgrastim-Aafi: uses, dosing, side effects & brands
Filgrastim-Aafi is a medicine sold in the U.S. under one brand, for neutropenia. Below: what the FDA label says, every product that contains it, what the pills look like, and its recall record.
Key facts
- Treats
- Neutropenia
- Available as
- Injectable
- Sold as
- Nivestym
- Prescription?
- Prescription only
- Generic available?
- Not in our catalog
How filgrastim-aafi is dosed
From the FDA label for Nivestym (application BLA761080). Other filgrastim-aafi products — different forms, different strengths — are dosed differently. Follow the label for the one you were prescribed.
Patients with cancer receiving myelosuppressive chemotherapy or induction and/or consolidation chemotherapy for AML. o Recommended starting dose is 5 mcg/kg/day subcutaneous injection, short intravenous infusion (15 to 30 minutes), or continuous intravenous infusion. See Full Prescribing Information for recommended dosage adjustments and timing of administration. ( 2.1 ) • Patients with cancer undergoing bone marrow transplantation. o 10 mcg/kg/day given as an intravenous infusion no longer than 24 hours. See Full Prescribing Information for recommended dosage adjustments and timing of administration. ( 2.2 ) • Patients undergoing autologous peripheral blood progenitor cell collection and therapy. o 10 mcg/kg/day subcutaneous injection. ( 2.3 ) o Administer for at least 4 days before first leukapheresis procedure and continue until last leukapheresis. ( 2.3 ) • Patients with congenital neutropenia. o Recommended starting dose is 6 mcg/kg subcutaneous injection twice daily. ( 2.4 ) • Patients with cyclic or idiopathic neutropenia. o Recommended starting dose is 5 mcg/kg subcutaneous injection daily. ( 2.4 ) • Direct administration of less than 0.3 mL (180 mcg) using NIVESTYM prefilled syringe is not recommended due to potential for dosing errors. ( 2.5 ) 2.1 Dosage in Patients with Cancer Receiving Myelosuppressive Chemotherapy or Induction and/or Consolidation Chemotherapy for…
Filgrastim-Aafi side effects
The following serious adverse reactions are discussed in greater detail in other sections of the labeling: • Splenic Rupture [see Warnings and Precautions (5.1) ] • Acute Respiratory Distress Syndrome [see Warnings and Precautions (5.2) ] • Serious Allergic Reactions [see Warnings and Precautions (5.3) ] • Sickle Cell Disorders [see Warnings and Precautions (5.4) ] • Glomerulonephritis [see Warnings and Precautions (5.5) ] • Alveolar Hemorrhage and Hemoptysis [see Warnings and Precautions (5.6) ] • Capillary Leak Syndrome [see Warnings and Precautions (5.7) ] • Myelodysplastic Syndrome [see Warnings and Precautions (5.8) ] • Acute Myeloid Leukemia [see Warnings and Precautions (5.8) ] • Thrombocytopenia [see Warnings and Precautions (5.9) ] • Leukocytosis [see Warnings and Precautions (5.10) ] • Cutaneous Vasculitis [see Warnings and Precautions (5.11) ] • Aortitis [see Warnings and Precautions (5.15) ] Most common adverse reactions in patients: • With nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs (≥ 5% difference in incidence compared to placebo) are pyrexia, pain, rash, cough, and dyspnea. ( 6.1 ) • With AML (≥ 2% difference in incidence) are pain, epistaxis and rash. ( 6.1 ) • With nonmyeloid malignancies undergoing myeloablative chemotherapy followed by BMT (≥ 5% difference in incidence) is rash. ( 6.1 ) • Undergoing peripheral blood progenitor cell…
Who shouldn’t take filgrastim-aafi
NIVESTYM is contraindicated in patients with a history of serious allergic reactions to human granulocyte colony-stimulating factors such as filgrastim products or pegfilgrastim products [see Warnings and Precautions (5.3) ] . Patients with a history of serious allergic reactions to human granulocyte colony-stimulating factors such as filgrastim products or pegfilgrastim products. ( 4 )
Every filgrastim-aafi product we track (1)
Same active ingredient — different manufacturer, form, price and FDA recall record. That last one is what our independent score measures.
Only one: Nivestym.
What people report to the FDA about filgrastim-aafi
The FDA Adverse Event Reporting System (FAERS) collects reports from patients and clinicians. It holds 27 reports naming filgrastim-aafi, and the FDA flagged 70% of those reports as serious. The effects reported most often — leaving out reports about overdose, misuse or the condition being treated, which dominate the raw list for common medicines:
- febrile neutropenia4 reports
- sepsis4 reports
- extradural haematoma3 reports
- subdural haematoma3 reports
- constipation2 reports
- cough2 reports
- diarrhoea2 reports
- dyspnoea2 reports
Read these as a signal, not a rate. A report does not mean filgrastim-aafi caused the effect — anyone can file one, and many describe people taking several medicines for several conditions. Crucially there is no denominator: FAERS does not record how many people took the drug, so these counts cannot be turned into “X% of patients” — a bigger number often just means a more widely used or more talked-about drug. Duplicates exist, and publicity drives reporting. For what is actually established, read the FDA label section above.
Source: openFDA drug/event (FAERS), retrieved July 25, 2026.
Related calculators
Frequently asked questions
What is filgrastim-aafi?
Nivestym (Filgrastim-Aafi) is a medication used to treat Neutropenia.
Can you take filgrastim-aafi with other medicines?
It depends on the medicine. We check it against the FDA labels rather than guessing: our interaction checker searches each drug's own label for the other and quotes what it says, naming the section it came from. Run filgrastim-aafi against whatever else you take — and remember that a label not naming a drug is not the same as that combination being safe.
What forms does filgrastim-aafi come in?
Across the brands we track, filgrastim-aafi is currently marketed as injectable, per the FDA's National Drug Code Directory. Each form is dosed differently — follow the label for the exact product you were prescribed.
Is there a generic filgrastim-aafi?
We do not currently list a generic-labelled filgrastim-aafi product. That does not always mean none exists — it means none appears under a generic name in the FDA data we track. Ask your pharmacist.
Cite this page
- APA
- pharmaranks. (2026, July 24). Filgrastim-Aafi: uses, dosing, side effects & brands. https://pharmaranks.com/drugs/filgrastim-aafi
- MLA
- “Filgrastim-Aafi: uses, dosing, side effects & brands.” pharmaranks, 24 July 2026, https://pharmaranks.com/drugs/filgrastim-aafi.
We summarise public FDA and NIH sources — for a clinical claim, cite the primary source we link to as well.
Sources: FDA openFDA drug label, National Drug Code Directory, and Enforcement (recall) database. This page reproduces public FDA data and is not medical advice. Dosing is set by your prescriber.
Read the full FDA label for filgrastim-aafi on DailyMed (NIH) ↗.